Literature DB >> 15132730

A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX).

A Crinò1, R Schiaffini, S Manfrini, C Mesturino, N Visalli, G Beretta Anguissola, C Suraci, D Pitocco, S Spera, S Corbi, M C Matteoli, I P Patera, M L Manca Bitti, C Bizzarri, P Pozzilli.   

Abstract

OBJECTIVE: Various adjuvant therapies have been introduced along with intensive insulin therapy in patients with recent onset type 1 diabetes. Nicotinamide (NA), administered at diagnosis of the disease, can have beneficial effects on the clinical remission rate, improve metabolic control and preserve or slightly increase beta-cell function, probably by reducing toxicity due to free oxygen radicals. Vitamin E, a known antioxidant, inhibits lipid peroxidation; this can lead to protection of islet beta cells from the combined effects of interleukin 1, tumor necrosis factor and gamma interferon. The aim of the present study was to investigate whether the addition of vitamin E to NA could improve metabolic control and the residual beta-cell function, as measured by C-peptide secretion, in children and adolescents with recent onset type 1 diabetes; patients were followed-up for 2 years after diagnosis. PATIENTS AND STUDY
DESIGN: Recent onset type 1 diabetes patients (n=64, mean age 8.8 years) were recruited by participating centres of the IMDIAB group. Thirty-two patients were randomized to NA (25 mg/kg body weight) plus vitamin E (15 mg/kg body weight); 32 patients acted as controls and received NA only at the same dose as above. Intensive insulin therapy was applied to both treatment groups.
RESULTS: There were three drop outs during the 2-year follow-up period. Overall, patients assigned to the NA+vitamin E group or the NA group did not significantly differ in terms of glycated hemoglobin (HbA1c) levels, insulin requirement or baseline C-peptide secretion. Patients diagnosed at an age of less than 9 years showed significantly reduced C-peptide levels compared with those aged over 9 years at diagnosis and at the 2-year follow-up but there were no differences between the NA and NA+vitamin E treated groups. However at 6 months, patients over 9 years of age treated with NA+vitamin E showed significantly higher C-peptide compared with the NA group (P<0.003). In both age groups and in the different treatment groups, C-peptide levels found at diagnosis were preserved 2 years later.
CONCLUSIONS: The use of NA alone, or in combination with vitamin E, along with intensive insulin therapy is able to preserve baseline C-peptide secretion for up to 2 years after diagnosis. This finding is of particular interest for pre-pubertal children with type 1 diabetes and has never been reported before.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15132730     DOI: 10.1530/eje.0.1500719

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  24 in total

1.  Metabolic signatures of exercise in human plasma.

Authors:  Gregory D Lewis; Laurie Farrell; Malissa J Wood; Maryann Martinovic; Zoltan Arany; Glenn C Rowe; Amanda Souza; Susan Cheng; Elizabeth L McCabe; Elaine Yang; Xu Shi; Rahul Deo; Frederick P Roth; Aarti Asnani; Eugene P Rhee; David M Systrom; Marc J Semigran; Ramachandran S Vasan; Steven A Carr; Thomas J Wang; Marc S Sabatine; Clary B Clish; Robert E Gerszten
Journal:  Sci Transl Med       Date:  2010-05-26       Impact factor: 17.956

Review 2.  Immunotherapy for type 1 diabetes.

Authors:  Davide Frumento; Moufida Ben Nasr; Basset El Essawy; Francesca D'Addio; Gian Vincenzo Zuccotti; Paolo Fiorina
Journal:  J Endocrinol Invest       Date:  2017-03-04       Impact factor: 4.256

3.  Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease.

Authors:  Mark A Atkinson; Matthias von Herrath; Alvin C Powers; Michael Clare-Salzler
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

Review 4.  Redox-Sensitive Innate Immune Pathways During Macrophage Activation in Type 1 Diabetes.

Authors:  Ashley R Burg; Hubert M Tse
Journal:  Antioxid Redox Signal       Date:  2017-11-27       Impact factor: 8.401

5.  Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.

Authors:  Susanne M Cabrera; Xujing Wang; Yi-Guang Chen; Shuang Jia; Mary L Kaldunski; Carla J Greenbaum; Thomas Mandrup-Poulsen; Martin J Hessner
Journal:  Eur J Immunol       Date:  2016-01-21       Impact factor: 5.532

6.  Nicotinamide Inhibits Ethanol-Induced Caspase-3 and PARP-1 Over-activation and Subsequent Neurodegeneration in the Developing Mouse Cerebellum.

Authors:  Alessandro Ieraci; Daniel G Herrera
Journal:  Cerebellum       Date:  2018-06       Impact factor: 3.847

Review 7.  Vitamin E in renal therapeutic regiments.

Authors:  Mohamed Alaa Thabet; James C M Chan
Journal:  Pediatr Nephrol       Date:  2006-09-21       Impact factor: 3.714

8.  The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication.

Authors:  Yi-Cheng Chang; Lee-Ming Chuang
Journal:  Am J Transl Res       Date:  2010-06-10       Impact factor: 4.060

Review 9.  Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide.

Authors:  Seon Beom Song; Jin Sung Park; Gu June Chung; In Hye Lee; Eun Seong Hwang
Journal:  Metabolomics       Date:  2019-10-05       Impact factor: 4.290

Review 10.  Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.

Authors:  T Staeva-Vieira; M Peakman; M von Herrath
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.